Masergy Releases 2019 SD-WAN Market Trends Report
Masergy, a leading provider of managed SD-WAN, cloud communications and managed security solutions, today announced results from its new 2019 SD-WAN Market Trends Survey, which found that security drives selection, skills gaps remain a primary obstacle to adoption, and adoption continues to rise.
The survey, conducted in partnership with IDG Research, analyzed responses from IT decision makers in global enterprises across a variety of industries. This survey was also conducted in 2017 as a benchmark in order to measure SD-WAN trends over time. Optimizing the network to support cutting-edge technology stands out as the most prominent objective that was covered in the survey. Most survey participants find that security is the biggest WAN challenge, even outweighing cost concerns. Managing numerous users, devices, and locations is also an increasing pain point.
Key findings from the 2019 survey include:
● Optimizing the network to support cutting-edge technologies remains the top WAN objective (61%) among survey participants.
● Security (50%) is the top WAN challenge and the leading factor (81%) guiding companies in the SD-WAN selection process.
● The skills gap (46%) remains a top barrier to SD-WAN adoption, whereas concerns regarding interoperability with existing WANs are less prevalent than they were two years ago.
● SD-WAN adoption rates increased from 35% to 54% over the past two years, with 90% of respondents’ actively researching, piloting, actively using or upgrading SD-WAN.
● Network management simplification (46%) continues to be the top expected IT benefit of SD-WAN adoption, and the top three expected business benefits of SD-WAN are increased efficiency, improved security, and cost savings.
“Masergy pioneered software-defined networking two decades ago, and this survey validates the growing maturity of SD-WAN solutions. IT leaders are tasked with transforming their business through cloud-based applications and emerging technologies, but these pivots introduce a new level of complexity that can be daunting for network and security teams,” said Masergy CEO James Parker. “Masergy is uniquely positioned to deliver on the digital ambitions of today’s global enterprises with our software-defined network, integrated security, and fully-managed SD-WAN services.”
Download Masergy’s 2019 SD-WAN Market Trends Report for a detailed view into the research results.
About Masergy
Masergy enables global enterprises to innovate, disrupt and dominate their industries with transformative solutions in managed SD-WAN, cloud communications and managed security. Built on the world’s most innovative Software Defined Platform, our agile technologies, customizable solutions, and unmatched customer experience are why leading organizations rely on Masergy to stay ahead of the competition. Be what’s next with Masergy. Learn more and follow us on our blog Transforming Enterprise IT, Twitter@Masergy, LinkedIn and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190716005291/en/
Contact information
Company Contact:
Sunita Mani
214.442.5740
sunita.mani@masergy.com
Media Contact:
Calin Gunn
802.779.7040
calin@bluetext.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom